RxDoctor Payments Data

Dan le, MD

Cardiovascular Disease · Westminster, CANPI 1912214347

Payments from drug & device makers

$5,434in general payments, 2019–2025

Across 106 payments — averaging $51.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$834
  • Amgen$513
  • Bayer$482
  • Johnson & Johnson$368
  • Actelion Pharmaceuticals US, Inc.$260
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$1,29324%
  • Food & beverage$4,14176%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,434 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,839,865
Medicare patients
1,337
Services billed
17,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban453$464,639
EntrestoSacubitril/Valsartan86$95,754
FarxigaDapagliflozin Propanediol80$79,945
XareltoRivaroxaban29$35,984
BrilintaTicagrelor50$34,079
VascepaIcosapent Ethyl16$13,171
Metoprolol Succinate774$9,452
MultaqDronedarone Hcl12$9,385
Ranolazine ErRanolazine54$5,148
Nitroglycerin321$5,109
Hydralazine Hcl328$3,820
Rosuvastatin Calcium193$2,966
Isosorbide Mononitrate ErIsosorbide Mononitrate232$2,837
Atorvastatin Calcium196$1,320
Losartan Potassium236$1,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$464,639453 claims
AstraZenecaFarxiga, Brilinta$181$114,024130 claims
NovartisEntresto$38$95,75486 claims
Johnson & JohnsonXarelto$368$35,98429 claims
Sanofi-aventis U.S. LLCMultaq$68$9,38512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →